Core Viewpoint - Crédit Agricole S.A. has made a redemption of €1.5 million to adjust the liquidity contract with Kepler Cheuvreux, which aims to create an active market for its shares on Euronext Paris. Group 1: Liquidity Contract Details - The liquidity contract was initially set at €50 million and has undergone several amendments since its inception on October 25, 2006, with the latest amendment on March 18, 2022 [1] - The redemption of €1.5 million was executed on December 19, 2025, to readjust the available amount for the liquidity contract [2] Group 2: Regulatory Compliance - The redemption was conducted in compliance with the MAR Regulation (EU No. 596/2014) and other relevant regulations, ensuring adherence to market abuse standards [3] Group 3: Position After Redemption - Following the redemption on December 19, 2025, the remaining position amounts to €43,442,934.57 and consists of 334,529 shares [4]

Core Viewpoint - Eric Vial has been elected as the new Chairman of the Board of Directors of Crédit Agricole S.A., succeeding Dominique Lefebvre, effective from January 1, 2026 [2]. Group 1: Appointment Details - The Board of Directors of Crédit Agricole S.A. unanimously elected Eric Vial as Chairman during their meeting on December 16, 2025 [2]. - Dominique Lefebvre's contributions and commitment during his 10-year tenure were commended by the Board [2]. Group 2: Biography and Experience - Eric Vial has been the Chairman of Crédit Agricole des Savoie since 2018 and has served as a director of Crédit Agricole S.A. since 2022 [4]. - He was elected Chairman of Fédération nationale du Crédit Agricole (FNCA) and SAS Rue La Boétie on December 4, 2025 [3]. - Vial has been involved in the cooperative sector and regional economy throughout his career, including his role as a breeder and founding chairman of the Savoie Breeders' Cooperative [5].

Group 1 - The article does not contain relevant content regarding company or industry insights [1]

Core Insights - First Principles Partners specializes in equity research focused on technology, innovation, and sustainability investment, utilizing a unique approach to identify overlooked investment opportunities [1] Group 1: Company Overview - First Principles Partners employs a "First Principles" methodology that breaks down complex financial and technological problems to their basic elements [1] - The firm has a strong background in investment, private equity, and venture capital, demonstrating a proven track record of delivering strong returns [1] Group 2: Investment Focus - The articles produced by First Principles Partners on Seeking Alpha concentrate on emerging technologies, sustainable investing, and the intersection of innovation and finance [1] - The company aims to share insights with a broader audience and engage with fellow investors to drive positive change in sustainability and innovation [1]

Core Insights - Oscar Health (OSCR) is a health insurance company primarily operating in the ACA marketplace across 18 states, focusing on individual health plans [1] Company Overview - Oscar Health specializes in providing health insurance plans to individuals, leveraging the ACA marketplace [1] Analyst Background - The analysis is conducted by an IMC qualified contributor with 5 years of experience in financial markets and over 2 years in primary investment research, focusing on smaller, under-covered companies for potential investment opportunities [1]

Core Viewpoint - Centene (CNC) is currently undervalued despite recent struggles, with potential upside linked to possible extensions of ACA insurance subsidies, which could positively impact its business model [1][4]. Company Overview - Centene is based in St. Louis and manages government-sponsored health insurance programs, including Medicaid, Medicare, and ACA plans [2]. - The current market capitalization of Centene is $19 billion, with a stock price of $39.32 [3]. Recent Performance - Centene's stock price has seen significant volatility, dropping from over $56 per share in July to below $26 in early August due to concerns over subsidy extensions and Medicaid cuts [5][6]. - The stock has rebounded nearly 19% over the past month, aided by better-than-expected earnings and revenue reports [7]. Market Influences - The stock's performance is closely tied to Medicare and Medicaid spending, as well as the status of ACA health plans [8]. - Recent reports suggest that President Trump may propose a two-year extension for ACA insurance subsidies, which could garner Republican support and benefit Centene as the largest provider in ACA marketplaces [4].

Core Insights - The Royce Small-Cap Trust aims for long-term capital growth by investing at least 65% of its assets in equity securities of small- and micro-cap companies [10] Performance Summary - As of October 31, 2025, the Net Asset Value (NAV) is $17.79, while the market price (MKT) is $16.00 [1] - Year-to-date performance shows a NAV return of 10.95% and a market return of 7.30% [1] - One-year performance indicates a NAV return of 13.89% compared to a market return of 15.14% [1] - Over three years, the NAV return is 15.22% and the market return is 13.51% [1] - The five-year NAV return is 12.41%, while the market return is 13.88% [1] - The ten-year NAV return stands at 11.12%, with the market return at 11.95% [1] Portfolio Diagnostics - The average market capitalization of the portfolio is $3.3285 billion [4] - The weighted average Price-to-Earnings (P/E) ratio is 18.3x, and the weighted average Price-to-Book (P/B) ratio is 2.2x [4] - The total net assets of the fund amount to $2.15 billion [4] Portfolio Composition - The top ten positions account for varying percentages of net assets, with IES Holdings at 2.3% and Assured Guaranty at 1.3% [9] - The leading sectors by percentage of net assets include Industrials (25.7%), Financials (20.2%), and Information Technology (13.7%) [9] Fund Characteristics - The Royce Small-Cap Trust is noted as the oldest and largest small-cap closed-end fund, with an average weekly trading volume of approximately 1,137,181 shares [8] - The fund's adviser has over 50 years of experience in small- and micro-cap investments [8]

Core Viewpoint - Arcosa (ACA) has been outperforming its peers in the Construction sector this year, with a year-to-date return of 3.1% compared to the sector average of -7.3% [4]. Group 1: Company Performance - Arcosa is currently ranked 2 (Buy) in the Zacks Rank system, indicating a positive earnings outlook [3]. - The Zacks Consensus Estimate for Arcosa's full-year earnings has increased by 10.8% over the past quarter, reflecting stronger analyst sentiment [3]. - In the Building Products - Miscellaneous industry, which includes 33 stocks, Arcosa is performing better than the industry average, which has seen a loss of about 8.2% this year [6]. Group 2: Sector Context - The Construction sector, which includes 92 individual stocks, currently holds a Zacks Sector Rank of 16, indicating its relative performance compared to other sectors [2]. - DIRTT Environmental Solutions Ltd. (DRTTF), another stock in the Construction sector, has also shown positive performance with a year-to-date return of 1.9% [4][5]. - Both Arcosa and DIRTT Environmental Solutions Ltd. are expected to maintain solid performance moving forward, making them noteworthy for investors interested in Construction stocks [7].

Core Insights - The article emphasizes the importance of identifying growth stocks that exhibit above-average financial growth, which can lead to solid returns for investors [1][2] Company Overview: Arcosa (ACA) - Arcosa is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 12.9%, but projected EPS growth for the current year is significantly higher at 41.6%, compared to the industry average of 7.4% [4] Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth being particularly attractive [3] - Arcosa's projected EPS growth of 41.6% this year positions it well above industry standards [4] Cash Flow Growth - Cash flow growth is essential for growth-oriented companies, allowing them to expand without relying on external funding [5] - Arcosa's year-over-year cash flow growth is currently at 8%, surpassing the industry average of 3.4% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 11.3%, compared to the industry average of 10.1% [6] Earnings Estimate Revisions - Positive trends in earnings estimate revisions correlate strongly with stock price movements [7] - Arcosa's current-year earnings estimates have been revised upward, with a 9.6% increase in the Zacks Consensus Estimate over the past month [8] Conclusion - Arcosa holds a Zacks Rank of 2 and a Growth Score of B, indicating strong potential for outperformance in the growth stock category [10]

Core Viewpoint - Arcosa (ACA) is currently viewed as a superior value opportunity compared to Installed Building Products (IBP) based on various financial metrics and earnings outlook [1][7]. Valuation Metrics - ACA has a forward P/E ratio of 22.89, while IBP has a forward P/E of 23.61, indicating that ACA is relatively cheaper [5]. - The PEG ratio for ACA is 1.43, suggesting a more favorable valuation in relation to its expected earnings growth compared to IBP's PEG ratio of 4.52 [5]. - ACA's P/B ratio stands at 1.86, significantly lower than IBP's P/B ratio of 9.78, further supporting ACA's valuation advantage [6]. Earnings Outlook - ACA is experiencing an improving earnings outlook, which is a positive indicator in the Zacks Rank model, contrasting with IBP's less favorable position [3][7].